Treatment with combined dabrafenib and trametinib in BRAFV600E-mutated metastatic malignant melanoma: a case of long-term complete response after treatment cessation

Sonia Brugnara, Mariacristina Sicher, Elena Maria Bonandini, Davide Donner, Franca Chierichetti, Mattia Barbareschi, Carlo Renè Girardelli, Orazio Caffo

Article Type

Case Report

Published

The case report discusses a patient, diagnosed with BRAFV600E-mutated metastatic malignant melanoma M1a, who achieved a complete metabolic response after 7 months of treatment with the combination of dabrafenib and trametinib.

Read more

Prognostic and predictive factors of eribulin efficacy in heavily pretreated patients affected by metastatic breast cancer: correlation with tumor biology and previous therapies

Sabrina Rossi, Alessandra Cassano, Antonia Strippoli, Giovanni Schinzari, Ettore D’Argento, Michele Basso, Carlo Barone

Article Type

Original Research

Published

This retrospective study looks to find specific predictive criteria related to patient or tumor characteristics in order to select patients that might benefit the most from eribulin and define the correct treatment sequence.

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.